Latest News & Features
article
The rise of so-called personalised medicine presents new challenges and opportunities for drugs companies, says Robert Andrews. 19 February 2014
article
It’s been a long time coming, but perhaps the Brazilian patent office is finally going to deal with the logjam of patent applications, says Gabriel di Blasi. 19 February 2014
Americas
In a global league, Canada’s biotech industry would be respectably mid table. LSIPR talks to Andrew Casey, president of industry association BIOTECanada, about how the organisation is trying to take it to the next level. 3 February 2014
article
Susana Soares is a designer inspired by scientific research to create objects that explore new aesthetic and behavioural opportunities. LSIPR investigated how she protects her work in a realm where life sciences and design collide. 3 February 2014
Big Pharma
Three December decisions from the Court Of Justice of the European Union shed light on supplementary protection certificates in Europe. 13 January 2014
Americas
Stem cells are seen by many as the great hope for medical research in the years to come. LSIPR spoke to Nicholas Seay, chief technology officer at Cellular Dynamics, about the importance of IP in this field. 13 January 2014
Americas
How can ‘big’ data help drug candidates through the pipeline? And who does the data belong to? LSIPR spoke to NuMedii chief executive Gini Deshpande. 3 December 2013
Asia-Pacific
As the largest science research institute in Japan, Riken has an important role in promoting innovation. LSIPR talked to Akihiro Fujita, director of the institute’s research cluster for innovation, about the place of intellectual property in that endeavour. 3 December 2013
Americas
The first US court decision applying the Myriad decision has landed, and it makes for interesting reading, as Antoinette Konski reports. 3 December 2013
Europe
Genomic Vision develops genetic screening tests for diagnostics and research. In the aftermath of the Myriad ruling, how can it use IP to develop market share? LSIPR spoke to chief executive Aaron Bensimon to find out. 4 November 2013